<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Diamedica Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc</link>
<description>Latest news and press releases for Diamedica Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/diamedica-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355e7978dffbe2df0ed310.webp</url>
<title>Diamedica Therapeutics Inc</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc</link>
</image>
<item>
<title>DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-full-year-2025-financial-results-and-provides-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-full-year-2025-financial-results-and-provides-business-highlights</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2</description>
</item>
<item>
<title>DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-to-report-fourth-quarter-2025-financial-results-and-provide-a-business-update-march-31-2026</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-to-report-fourth-quarter-2025-financial-results-and-provide-a-business-update-march-31-2026</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments</description>
</item>
<item>
<title>DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-receives-health-canada-clearance-to-initiate-phase-2-study-of-dm199-in-preeclampsia-10</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-receives-health-canada-clearance-to-initiate-phase-2-study-of-dm199-in-preeclampsia-10</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>“No Objection Letter” from Health Canada enables initiation of Phase 2 DM199 study in early-onset preeclampsia DM199 Preeclampsia program featured in recent</description>
</item>
<item>
<title>DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-to-participate-in-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-to-participate-in-upcoming-march-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments</description>
</item>
<item>
<title>DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-announces-inducement-grants-under-220000483</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-announces-inducement-grants-under-220000483</guid>
<pubDate>Fri, 16 Jan 2026 22:00:00 GMT</pubDate>
<description>MINNEAPOLIS, January 16, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in December 2025. The stock options were a material inducement to the emplo</description>
</item>
<item>
<title>DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-provides-dm199-preeclampsia-134500339</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-provides-dm199-preeclampsia-134500339</guid>
<pubDate>Thu, 18 Dec 2025 13:45:00 GMT</pubDate>
<description>MINNEAPOLIS, December 18, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA’s request for one additional non-clinical,</description>
</item>
<item>
<title>DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-third-quarter-213000154</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-third-quarter-213000154</guid>
<pubDate>Wed, 12 Nov 2025 21:30:00 GMT</pubDate>
<description>MINNEAPOLIS, November 12, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction and acute ischemic stroke (AIS), today provided a business update and reported financial results for the third quarter ended September 30, 2025. Management will host a conference call on Thursday, November 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update</description>
</item>
<item>
<title>DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-participate-jefferies-global-131500456</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-participate-jefferies-global-131500456</guid>
<pubDate>Mon, 10 Nov 2025 13:15:00 GMT</pubDate>
<description>MINNEAPOLIS, November 10, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.</description>
</item>
<item>
<title>DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-report-third-quarter-211500762</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-report-third-quarter-211500762</guid>
<pubDate>Thu, 06 Nov 2025 21:15:00 GMT</pubDate>
<description>MINNEAPOLIS, November 06, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12th. DiaMedica will host a live conference call on Thursday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financia</description>
</item>
<item>
<title>DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments</description>
</item>
<item>
<title>DiaMedica Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-participate-upcoming-investor-123000154</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-participate-upcoming-investor-123000154</guid>
<pubDate>Fri, 05 Sep 2025 12:30:00 GMT</pubDate>
<description>MINNEAPOLIS, September 05, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in two upcoming investor conferences in New York City.</description>
</item>
<item>
<title>DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-participate-cantor-global-122300120</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-participate-cantor-global-122300120</guid>
<pubDate>Tue, 02 Sep 2025 12:23:00 GMT</pubDate>
<description>MINNEAPOLIS, September 02, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City from September 3-5, 2025.</description>
</item>
<item>
<title>DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-second-quarter-201500498</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-second-quarter-201500498</guid>
<pubDate>Tue, 12 Aug 2025 20:15:00 GMT</pubDate>
<description>MINNEAPOLIS, August 12, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2025. Management will host a conference call Wednesday, August 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 20</description>
</item>
<item>
<title>DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-appoints-julie-krop-120000983</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-appoints-julie-krop-120000983</guid>
<pubDate>Wed, 06 Aug 2025 12:00:00 GMT</pubDate>
<description>MINNEAPOLIS, August 06, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons.</description>
</item>
<item>
<title>DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-report-second-quarter-201500913</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-report-second-quarter-201500913</guid>
<pubDate>Tue, 05 Aug 2025 20:15:00 GMT</pubDate>
<description>MINNEAPOLIS, August 05, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial resu</description>
</item>
<item>
<title>DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-announces-closing-30-203000698</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-announces-closing-30-203000698</guid>
<pubDate>Wed, 23 Jul 2025 20:30:00 GMT</pubDate>
<description>MINNEAPOLIS, July 23, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common shares to accredited investors. The Company sold approximately 8.6 million common shares at a purchase price of $3.50 per share. After deducting estimated offering expenses, the</description>
</item>
<item>
<title>DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-raises-30-million-120000739</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-raises-30-million-120000739</guid>
<pubDate>Mon, 21 Jul 2025 12:00:00 GMT</pubDate>
<description>MINNEAPOLIS, July 21, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction.</description>
</item>
<item>
<title>DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-positive-interim-120000889</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-reports-positive-interim-120000889</guid>
<pubDate>Thu, 17 Jul 2025 12:00:00 GMT</pubDate>
<description>MINNEAPOLIS, July 17, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase, reinforcing the therapeutic potential of DM199. DM199, rinvecalinase alfa, is a recombinant form of the KLK1 protein expected to influence blood pressure regulatio</description>
</item>
<item>
<title>DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-announces-inclusion-russell-123000462</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-announces-inclusion-russell-123000462</guid>
<pubDate>Tue, 24 Jun 2025 12:30:00 GMT</pubDate>
<description>MINNEAPOLIS, June 24, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27.</description>
</item>
<item>
<title>DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-present-jefferies-global-123000689</link>
<guid isPermaLink="true">https://6ix.com/company/diamedica-therapeutics-inc/news/diamedica-therapeutics-present-jefferies-global-123000689</guid>
<pubDate>Thu, 22 May 2025 12:30:00 GMT</pubDate>
<description>MINNEAPOLIS, May 22, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025.</description>
</item>
</channel>
</rss>